VJOncology is committed to improving our service to you

ESMO 2019 | The value of PD-L1 as a biomarker beyond lung cancers

VJOncology is committed to improving our service to you

Kevin Harrington

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, explains to us the value of PD-L1 as a biomarker, focusing on head and neck squamous cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter